Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Protagonist Therapeutics Inc
(NQ:
PTGX
)
36.10
+0.55 (+1.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Protagonist Therapeutics Inc
< Previous
1
2
Next >
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...
Via
FinancialNewsMedia
Protagonist Therapeutics to Present at Upcoming Investor Conferences
September 05, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
August 16, 2023
Via
ACCESSWIRE
Protagonist Receives $34 Million from Warrant Exercises
August 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
June 01, 2023
Via
Investor Brand Network
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
July 18, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
July 04, 2023
Via
ACCESSWIRE
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
June 28, 2023
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
June 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 06, 2023
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 04, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
April 04, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
March 15, 2023
Via
ACCESSWIRE
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing
June 27, 2022
San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
April 29, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
April 29, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
April 21, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
April 20, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGX
April 20, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm
September 22, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.